;
PT. Meiji Indonesian Pharmaceutical Industries
About Us

Company History

2020

2020

This year has been a difficult year for many companies due to the Covid-19 pandemic that has hit the world. However, this year PT. Meiji Indonesia can still spread its wings by launching several new products from the Ethical sector and also OTC sector, namely Babydex-A® MS Cream.

2019

2019

To support our strategic moves and initiatives, we have accomplished our strategic expansion of our facilities, including our new Head Office to ensure long-term journey to serve the country and the world. Further expansion of our product portfolio continues to take place with the introduction of the new products in OTC sector - Ediva Series®, and Ophthalmology products in the Ethical sector.

2018

2018

In line with the increasing production capacity, a new warehouse occupying 1,377 sqm of space, dedicated for ß-Lactam product packaging materials was officially in use.

2017

2017

A new product under Skin Care category - Sakura Collagen®, was launched, followed by a Household Medical Supplies Product - Rubysta®.

2016

2016

A baby product - Babydex-A®, was launched in line with the Company's conception of new values.

 

 

2014

2014

On May 13th, 2014, PT. Meiji Indonesia celebrated its 40th anniversary in Surabaya.

2013

2013

The lyophilized project was established to produce lyophilized sterile injection. This new facility has even widely spanned our penetration of specific medicine demanded by global market.

 

2011

2011

In order to guarantee the quality of our new materials, in this year we established our API production facility. The API is formulated through a series of examinations, improvements, and verifications. Then, the raw materials are processed into finished products which are exported to overseas market.

 

2009

2009

We received a series of awards from Meiji Headquarters in Japan as the highest business performance among Meiji Group globally in 2009, 2010, 2013, 2015,2016, and 2018.

 

2001

2001

The establishment of ß-Lactam 3 plant was completed to meet export demand.

1997

1997

Establishment of ß-Lactam 2 plant was completed.

1994

1994

The Food and Drug Administration (BPOM) issues Good Manufacturing Practices (GMP) certificates for all product categories. The awarding of this certificate encourages the achievement of certification for our production quality in the following years.

 

1983

1983

Meiji Seika Kaisha (currently Meiji Seika Pharma Co., Ltd.) Japan granted a trust to produce Kanamycin API (Active Pharmaceutical Ingredient) since 1983-1991, followed by Ampicillin API since 1991-1998.

1982

1982

In compliance with GMP (Good Manufacturing Practices) regulation, ß-Lactam and Non ß-Lactam production must be placed under separate building, therefore the ß-Lactam 1 plant was established as a continuation of this regulation.

1974

1974

A ß-Lactam facility at Bangil was the early origin of our present enterprise.